Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus,

Slides:

Advertisements

Similar presentations

1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 4.1 Chapter 4.

Advertisements

Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Adaptation to Natural Binocular Disparities in Primate V1 Explained by a Generalized Energy Model Ralf M. Haefner, Bruce G. Cumming Neuron Volume 57, Issue.

Small-Cell Carcinoma in Association With a Mature Cystic Teratoma of the Ovary: A Case Report With Literature Review Karina E. Hew, Kimberley Studeman,

Podocalyxin-Like Protein 1 Expression and Correlation with Clinical Characteristics in Epithelial Serous and Mucinous Ovarian Carcinoma and Tumor-Like.

Volume 144, Issue 1, Pages (January 2017)

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma Q. Le, A.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Is Early Placement Better in Alzheimer's Disease?

Volume 145, Issue 1, Pages (April 2017)

Noha Abd ElRahim Aboulhagag, Rana Fathy Torky, Sabah Ahmed Fadel

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 24, Issue 2, Pages (June 2017)

Volume 132, Issue 2, Pages (February 2014)

Volume 148, Issue 1, Pages (January 2018)

A Molecular Code for Imprinting Drug-Cue Associations

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 150, Issue 3, Pages (September 2018)

Volume 132, Issue 2, Pages (February 2014)

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Diagnostic Value of Albumin Gene Expression in Liver Tumors: Case Report and Review of the Literature S. Vincent Rajkumar, M.D., Ronald L. Richardson,

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 147, Issue 1, Pages 3-10 (October 2017)

Volume 141, Issue 2, Pages (May 2016)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma Tsuyoshi Noguchi, MD, PhD, Shinsuke Takeno, MD, PhD, Tomotaka.

Volume 152, Issue 1, Pages (January 2019)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 130, Issue 3, Pages (September 2013)

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 150, Issue 1, Pages (July 2018)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

Role of Chromosome 3q Amplification in Lung Cancer

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Volume 139, Issue 3, Pages (December 2015)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 3, Pages (September 2013)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Organization news Archives of Physical Medicine and Rehabilitation

Volume 152, Issue 1, Pages (January 2019)

Volume 26, Issue 2, Pages (June 2019)

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 152, Issue 1, Pages (January 2019)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Presentation transcript:

Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus, Synnöve Staff, Arto Leminen, Jorma Isola, Ralf Butzow Gynecologic Oncology Volume 125, Issue 1, Pages 282-283 (April 2012) DOI: 10.1016/j.ygyno.2011.12.437 Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 1 Examples of immunohistochemical staining and CISH of Aurora-A: (A) normal serous epithelium of fallopian tube with Aurora-A immunostaining, (B) normal ovarian surface epithelium with Aurora-A immunostaining, (C) serous ovarian carcinoma showing negative immunostaining of Aurora-A, (D) serous ovarian carcinoma showing positive cytoplasmic immunostaining of Aurora-A, (E) serous ovarian carcinoma showing positive nuclear immunostaining of Aurora-A, (F) serous ovarian carcinoma showing Aurora-A gene amplification by CISH, (G) normal serous epithelium of fallopian tube with immunostaining of phosphorylated Aurora-A, (H) serous ovarian carcinoma showing negative immunostaining of phosphorylated Aurora-A and (I) serous ovarian carcinoma showing positive immunostaining of phosphorylated Aurora-A. Gynecologic Oncology 2012 125, 282-283DOI: (10.1016/j.ygyno.2011.12.437) Copyright © 2011 Elsevier Inc. Terms and Conditions